Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 16/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325411 | 0.78 | MAPT (0.56) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL3328576 | 0.73 | PTGES (0.47) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL14125147 | 0.69 | PTGDR2 (0.42) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29887278 | 0.66 | NPC1 (0.48) | CYP3A4CYP2C19NPC1RAB9AMC4R | |
| SCHEMBL15969116 | 0.66 | HPGD (0.54) | NPC1RAB9A | |
| SCHEMBL6641245 | 0.66 | XDH (0.51) | — | |
| SCHEMBL802491 | 0.65 | PTGES (0.44) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL2564559 | 0.64 | GUSB (0.58) | — | |
| SCHEMBL3325970 | 0.64 | PIM1 (0.68) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL6267736 | 0.64 | NPC1 (0.48) | PTGESNPC1RAB9AMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2008133955-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | EXELIXIS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | PIM1 1/4885CSNK2A2 61/4885CSNK2B 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.